S2L Stock Chart & Stats
€14.00
€0.20(1.45%)
At close: 4:00 PM EDT
€14.00
€0.20(1.45%)
Day’s Range― - ―
52-Week Range€11.40 - €15.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.19B
Enterprise Value€10.72K
Total Cash (Recent Filing)€367.00M
Total Debt (Recent Filing)€5.12B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 04, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding357,165,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.14Price Target Upside22.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.68
Revenue Forecast (FY)€4.76B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue GrowthSustained, multi-segment revenue growth reflects a diversified business model across Pharmaceuticals, Surgical and Vision Care. This reduces single-market dependence, supports stable cash conversion and provides multiple organic levers (product launches, premium mix, geographic expansion) to sustain growth over 2–6 months and beyond.
Improving Cash Generation & DeleveragingPositive operating and free cash flow after prior weakness indicates stronger internal funding capacity and operational discipline. Improved cash conversion supports ongoing capex and R&D while enabling gradual debt reduction, bolstering financial flexibility and lowering structural refinancing risk over the medium term.
Margin Expansion And Productivity GainsHigher gross and EBITDA margins driven by premium product mix and productivity imply sustainable unit economics. When backed by disciplined SG&A and sustained premium sales (e.g., premium IOLs), margin expansion can persist and compound free cash flow, supporting reinvestment and deleveraging over the next several quarters.
Bears Say
Elevated Leverage & Interest BurdenHigh net leverage and material interest costs constrain financial flexibility and absorb operating cash flow, making the company more sensitive to slower growth or margin pressure. Servicing significant debt could limit strategic optionality, prolong deleveraging and increase refinancing exposure over the medium term.
Ongoing GAAP Net Losses / Negative ROEPersistent GAAP losses and negative ROE indicate the company has not yet converted revenue scale into shareholder returns. This structural profitability gap raises dependence on adjusted metrics and cash flow to show progress, and delays true equity value compounding until sustained GAAP profitability is achieved.
Pipeline & Regulatory Execution RiskSignificant near-term product milestones remain unresolved. Clinical or regulatory setbacks would impair projected revenue and margin trajectories tied to new launches (MIGS, dry eye, enVista Beyond). Execution risk here can materially affect medium-term growth and the payback timeline on elevated R&D investment.
Bausch + Lomb Corporation News
S2L FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was €11.40 and its highest was €15.70 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is €5.19B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 82 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 29, 2026. The company reported €0.13 earnings per share for the quarter, missing the consensus estimate of €0.133 by -€0.003.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.18.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 357,165,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of €0.13 in its last earnings report, missing expectations of €0.133. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in DE:S2L
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€17.14 (22.41% Upside)
€17.14 (22.41% Upside)
Blogger Sentiment
Bullish
DE:S2L Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
S2L Company Deck
S2L Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum across revenue, margin expansion, cash generation and deleveraging. Broad-based growth across segments (Pharmaceuticals, Surgical, Vision Care), robust adjusted EBITDA growth, raised guidance and continued R&D investment were emphasized as evidence that the three-year plan is on track. Notable risks include elevated leverage and interest expense, macro/currency sensitivity (consumer demand tied to gas prices), ongoing regional disruptions (e.g., strikes), competitive dynamics in surgical and dry eye markets, and several important clinical and regulatory milestones still pending. Overall, the positives in growth, margins, cash flow and guidance upgrades substantially outweigh the outlined risks.View all DE:S2L earnings summariesS2L Stock 12 Month Forecast
Average Price Target
€17.14
▲(22.41% Upside)